2026-10-21. The following slide deck was published by 4D Molecular Therapeutics, Inc.
About This Event4D Molecular Therapeutics (Nasdaq: FDMT), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT rings the Closing Bell.
EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 13, 2026, the compensation committee of the Company’s board of directors granted 13 new non-executive employees options to purchase an aggregate of 260,000 shar
Detailed price information for Viking Thera (VKTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.
Investing.com -- B. Riley Securities reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics, citing the launch of a Phase 3 trial in diabetic macular edema and encouraging two-year data for its lead gene therapy candidate.
4D Molecular Therapeutics (FDMT) has enrolled the first patients in a phase 3 trial of 4D-150 in dia
4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating 4D-150 in a treatment-naïve DME populationUpdated 2-year data from SPECTRA Part 1 clinical trial in DME continue to demonstrate a favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction EMERYVILLE, Calif., Sept. 28, 2
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
David Kirn, Director, President and Chief Executive Officer, on September 14, 2026, sold 58,333 shar
Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.
4D Molecular Therapeutics (FDMT) has an average rating of buy and mean price target of $28, accordin
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in September: Wells Fargo 2026 Healthcare Conference: Wednesday, September
This is the newest page. Registered accounts read further back.